These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
252 related items for PubMed ID: 29391598
1. Decreased TGFBR3/betaglycan expression enhances the metastatic abilities of renal cell carcinoma cells through TGF-β-dependent and -independent mechanisms. Nishida J, Miyazono K, Ehata S. Oncogene; 2018 Apr; 37(16):2197-2212. PubMed ID: 29391598 [Abstract] [Full Text] [Related]
2. Effects of TGF-β signaling in clear cell renal cell carcinoma cells. Boström AK, Lindgren D, Johansson ME, Axelson H. Biochem Biophys Res Commun; 2013 May 24; 435(1):126-33. PubMed ID: 23618868 [Abstract] [Full Text] [Related]
6. TGFBR3, a potential negative regulator of TGF-β signaling, protects cardiac fibroblasts from hypoxia-induced apoptosis. Chu W, Li X, Li C, Wan L, Shi H, Song X, Liu X, Chen X, Zhang C, Shan H, Lu Y, Yang B. J Cell Physiol; 2011 Oct 24; 226(10):2586-94. PubMed ID: 21792916 [Abstract] [Full Text] [Related]
7. Betaglycan (TGFBR3) up-regulation correlates with increased TGF-β signaling in Marfan patient fibroblasts in vitro. Groeneveld ME, Bogunovic N, Musters RJP, Tangelder GJ, Pals G, Wisselink W, Micha D, Yeung KK. Cardiovasc Pathol; 2018 Oct 24; 32():44-49. PubMed ID: 29198452 [Abstract] [Full Text] [Related]
9. Transforming growth factor-β promotes aggressiveness and invasion of clear cell renal cell carcinoma. Sitaram RT, Mallikarjuna P, Landström M, Ljungberg B. Oncotarget; 2016 Jun 14; 7(24):35917-35931. PubMed ID: 27166254 [Abstract] [Full Text] [Related]
10. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. Cancer Res; 2007 Feb 01; 67(3):1090-8. PubMed ID: 17283142 [Abstract] [Full Text] [Related]
11. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling. Jiang HL, Sun HF, Gao SP, Li LD, Hu X, Wu J, Jin W. Oncotarget; 2015 Jun 30; 6(18):16352-65. PubMed ID: 25970785 [Abstract] [Full Text] [Related]
18. Decreased expression of the type III TGF-β receptor enhances metastasis and invasion in hepatocellullar carcinoma progression. Zhang S, Sun WY, Wu JJ, Gu YJ, Wei W. Oncol Rep; 2016 Apr 30; 35(4):2373-81. PubMed ID: 26882862 [Abstract] [Full Text] [Related]
19. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma. Li T, Cheng Y, Wang P, Wang W, Hu F, Mo X, Lv H, Xu T, Han W. J Exp Clin Cancer Res; 2015 Oct 16; 34():122. PubMed ID: 26474560 [Abstract] [Full Text] [Related]
20. N6-methyladenosine enhances the expression of TGF-β-SMAD signaling family to inhibit cell growth and promote cell metastasis. Peng B, Cheng S, Wang H, Liu T, Gu Y, Duan L, Cheng T, Wang X, Wang X, Zhang Q, Zhang Y, Zhao X, Yao X, Zhao X, Song D, Zeng J, Gao S. Cancer Lett; 2024 Oct 28; 603():217195. PubMed ID: 39222678 [Abstract] [Full Text] [Related] Page: [Next] [New Search]